The new research team will work on multispecific biologics to target innovative pathways in the tumor microenvironment (TME).

新的研究团队将致力于多特异性生物制剂，以靶向肿瘤微环境（TME）中的创新通路。

HEIDELBERG, Germany, October 23, 2025 / Biotech Newswire / --

德国海德堡，2025年10月23日 /生物技术新闻社/ --

BioMed X

BioMed X

, a leading innovation hub for pharma, today announced the start of a new research team at its Heidelberg institute for multispecific biologics in the field of immuno-oncology in collaboration with

，一个领先的制药创新中心，今天宣布在其海德堡研究所启动一个新的研究团队，专注于免疫肿瘤学领域的多特异性生物制品，与之合作的是

Daiichi Sankyo

第一三共

(TSE: 4568) through its Daiichi Sankyo Research Institute in Munich. This new project, led by BioMed X boot camp winner

（东证：4568）通过其位于慕尼黑的第一三共研究所。这个新项目由BioMed X训练营的获奖者领导。

Dr. Reda Benmebarek

雷达·本梅巴雷克博士

, will explore next-generation biologics as a potential strategy to transform how solid tumors are treated.

，将探索下一代生物制剂作为潜在策略，以改变实体瘤的治疗方法。

“The ability of multispecific biologics to engage multiple targets simultaneously represents a powerful strategy to overcome the limitations of conventional therapies,”

“多特异性生物制剂能够同时作用于多个靶点，这代表了一种克服传统疗法局限性的有力策略。”

explains Dr. Reda Benmebarek.

雷达·本梅巴雷克博士解释道。

“By targeting the microenvironment with new biologic scaffolds, we aim to simultaneously recruit immune cells and activate potent immune responses that could potentially increase the efficacy of solid tumor therapy.”

“通过使用新型生物支架靶向微环境，我们旨在同时招募免疫细胞并激活强效的免疫反应，这可能会提高实体瘤治疗的疗效。”

Before joining BioMed X as a group leader, Dr. Benmebarek was a post-doctoral fellow at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, and at Ludwig-Maximilians-Universität München in Munich, Germany where his research focused on mechanisms that govern response and resistance to immunotherapeutics within the tumor microenvironment..

在加入 BioMed X 担任组长之前，Benmebarek 博士曾是美国马里兰州贝塞斯达国立卫生研究院 (NIH) 以及德国慕尼黑路德维希-马克西米利安大学的博士后研究员，他的研究重点是肿瘤微环境中控制对免疫治疗药物产生反应和耐药性的机制。

“We are excited to work with Daiichi Sankyo and bring together the innovative minds of both companies to improve cancer therapy,”

“我们很高兴能与第一三共合作，汇集两家公司的创新思维，以改进癌症治疗。”

said Dr. Thomas Rückle, Head of Research Europe at BioMed X.

欧洲生物医药研究中心负责人托马斯·吕克尔博士说。

“This collaboration demonstrates our commitment to developing innovative multispecific platforms that may provide more effective treatment options for patients with solid tumors.”

“此次合作展示了我们致力于开发创新的多特异性平台，这可能为实体瘤患者提供更有效的治疗选择。”

BioMed X’s innovation model provides fertile ground for high-risk, high-reward science. With sites in Heidelberg and New Haven, and satellite research teams embedded directly within pharma R&D environments, BioMed X offers a collaborative space where top talents from academia and industry work side by side.

BioMed X的创新模式为高风险、高回报的科学研究提供了肥沃的土壤。公司在海德堡和纽黑文设有站点，并在制药研发环境中嵌入了卫星研究团队，BioMed X提供了一个协作空间，让来自学术界和工业界的顶尖人才并肩工作。

This collaboration with Daiichi Sankyo underscores BioMed X’s role as a truly global innovation hub. By connecting leading minds from around the world, BioMed X accelerates the translation of disruptive scientific ideas into new therapeutic concepts with worldwide impact..

这次与第一三共的合作突显了BioMed X作为全球创新中心的地位。通过汇聚全球顶尖人才，BioMed X加速了颠覆性科学理念向具有全球影响力的全新治疗概念的转化。

The new research team will join five other groups at the BioMed X Institute in Heidelberg, Germany, as well as two international teams: one at the BioMed X Institute in New Haven, Connecticut, USA and another at its XSeed Labs in Ridgefield, Connecticut, an innovation accelerator located on the campus of Boehringer Ingelheim in the USA..

新的研究团队将加入位于德国海德堡的 BioMed X 研究所的另外五个小组，以及两个国际团队：一个位于美国康涅狄格州纽黑文的 BioMed X 研究所，另一个位于其位于美国康涅狄格州里奇菲尔德的 XSeed 实验室，该创新加速器设在勃林格殷格翰美国校区内。

For high resolution please click the image.

请点击查看高清图片。

About

关于

BioMed X

生物医学X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, women’s health, cardiometabolic diseases, platform technologies, and artificial intelligence.

BioMed X 是一家独立的研究机构，在德国海德堡、美国康涅狄格州纽黑文、康涅狄格州里奇菲尔德的 XSeed 实验室以及全球范围内的合作伙伴地点设有站点。我们立足于学术界与工业界之间的交界面，致力于在肿瘤学、免疫学、神经科学、女性健康、心代谢疾病、平台技术及人工智能领域开展生物医学研究以及药物发现与开发。

.

。

All our research projects are supported by leading pharmaceutical companies or other external funding sources and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research..

我们所有的研究项目都得到了领先的制药公司或其他外部资金来源的支持，并由从世界各地顶尖学校招聘的早期职业科学家开展。通过将全球众包与本地孵化最优秀的人才和创意相结合，我们能够解决生物医学研究中最大的挑战。

We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.

我们致力于自由、创造性和好奇心驱动的研究，并结合对结果、时间表和可交付成果的坚实验证。我们通过利用协同作用，促进跨学科的交叉融合，在推动转化生物医学方面发挥着巨大的作用。

Contact

联系

BioMed X

生物医学X

Maria Morganti

玛丽亚·莫甘蒂

VP, Head of Marketing & Communications

副总裁，营销与传播主管

+49 6221 42611 30

+49 6221 42611 30

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

Keywords: Biomedical Research; Tumor Microenvironment; Neoplasms; Immunotherapy; BioMed X; Daiichi Sankyo; multispecific biologics; immuno-oncology; tumor microenvironment (TME); solid tumors; cancer therapy; immune activation; Dr. Reda Benmebarek; BioMed X boot camp; Dr. Thomas Rückle; pharma collaboration; academic-industry partnership; drug discovery and development; oncology research; immunology research; biomedical research; translational biomedicine; global research network; crowdsourced research model; early-career scientists.

关键词：生物医学研究；肿瘤微环境；肿瘤；免疫治疗；BioMed X；第一三共；多特异性生物制品；免疫肿瘤学；肿瘤微环境（TME）；实体瘤；癌症治疗；免疫激活；雷达·本梅巴雷克博士；BioMed X训练营；托马斯·吕克勒博士；制药合作；学术-行业合作；药物发现与开发；肿瘤学研究；免疫学研究；生物医学研究；转化生物医学；全球研究网络；众包研究模式；早期职业科学家。

Source: Biotech Newswire

来源：生物技术新闻swire